TEVATEVA PHARMACEUTICAL INDUSTR...

NYSE tevapharm.com


$ 17.35 $ 0.49 (2.91 %)    

Tuesday, 11-Jun-2024 15:59:58 EDT
QQQ $ 468.10 $ 3.19 (0.69 %)
DIA $ 388.08 $ -1.32 (-0.34 %)
SPY $ 537.01 $ 1.29 (0.24 %)
TLT $ 91.83 $ 0.94 (1.03 %)
GLD $ 214.15 $ 0.61 (0.29 %)
$ 17.34
$ 16.84
$ 0.00 x 0
$ 17.36 x 1,400
$ 16.78 - $ 17.63
$ 7.27 - $ 17.63
11,000,487
na
19.64B
$ 1.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-12-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 02-10-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 07-27-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-10-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-21-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 02-12-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.reuters.com/legal/litigation/amneal-us-ftc-win-order-removing-teva-inhaler-patents-fda-list-2024-06-10/ Drugmaker A...

 barclays-maintains-overweight-on-teva-pharmaceutical-indus-raises-price-target-to-21

Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...

 teva-announced-saturday-switching-to-uzedy-at-four-weeks-after-the-last-dose-of-once-monthly-paliperidone-palmitate-provided-the-most-comparable-pharmacokinetic-profile-based-on-the-relevant-pk-modeling-data-for-schizophrenia

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),today announced the present...

 b-of-a-securities-maintains-buy-on-teva-pharmaceutical-indus-raises-price-target-to-21

B of A Securities analyst Jason Gerberry maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price tar...

 reported-earlier-tevas-austedo-xr-receives-fda-green-light-one-pill-once-daily-dosage-now-available-for-td-and-hd-chorea

U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility wit...

 cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks-to-watch

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...

 piper-sandler-reiterates-overweight-on-teva-pharmaceutical-indus-raises-price-target-to-20

Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price...

 these-10-large-cap-stocks-shined-brightest-last-week-may-5-may-11-2024-are-they-in-your-portfolio

Toast, Teva, Vistra, Equinix, Applovin, IFF, Constellation, Emerson, IP, and STERIS were top performers last week. Are they in ...

 barclays-maintains-overweight-on-teva-pharmaceutical-indus-raises-price-target-to-20

Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...

 generics-player-teva-pharmaceutical-aces-late-stage-schizophrenia-drug-study-stock-shoots-higher

Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzap...

 wall-street-poised-for-muted-open-on-mixed-earnings-with-more-fed-speeches-in-store-analyst-sees-sp-500-crossing-late-march-high

U.S. stocks are on track for a mixed start on Wednesday as the market digests mixed earnings reports and looks ahead to more sp...

 teva-pharmaceuticals-and-medincell-say-phase-3-efficacy-results-from-solaris-trial-for-schizophrenia-showed-that-tev-749-met-its-primary-endpoint-as-measured-by-a-change-in-the-panss-total-score-from-baseline-after-8-weeks-compared-to-placebo

The study met its primary endpoint achieving clinically meaningful and statistically significant reductions across all TEV-‘7...